European watchdog wants to manage “risks” of early contacts between regulators, biopharma
→ At the FDA, the focus is on getting started as early as possible in talks with biopharma companies aimed at guiding development of new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
